← Leaderboards
Emmy Okello
Cincinnati Childrens Hosp Med Ctr
$3,039,271
Attributed
$6,402,153
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2022–25$2.5M$1.9M$1.3M$625K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$6,402,153 · 3
By mechanism
R33$3,518,173 · 1
R61$1,913,148 · 1
D43$970,832 · 1
Top collaborators
- Andrea Zawacki Beaton7 shared
- Nelson K Sewankambo4 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Andrea Zawacki Beaton$4,254,409
- Pirooz Eghtesady$2,834,838
- Joshua Morris Langberg$2,799,155
- David A Watkins$1,215,138
- Katherine Ann Scott Auger$1,482,181
Others in their field
Other Rising Stars on “Collaborations”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Gary Mays · Axle Informatics, Llc$65,040,187
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Jeffrey Leintz · National Opinion Research Center$38,969,238
- Brian Zavertnik · Palantir Technologies, Inc.$37,240,166
Research focus
CollaborationsChildRheumatic Heart DiseaseEnsurePoliciesLow And Middle-Income CountriesPersonsResourcesUgandaGuidelinesTrainingRecruitCaringCareer DevelopmentAfrica South Of The SaharaBurden Of IllnessAfricanGrantHeartFellowshipFundingClinical TrialsE-LearningGender
Grant awards (7)
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A non-inferiority randomized trial. (GOALIE)$1,740,115
R33 · FY2025 · HL
Reducing the Impact of Rheumatic Heart Disease across the Life Span: The Impact Program$242,643
D43 · FY2025 · TW
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A non-inferiority randomized trial. (GOALIE)$1,778,058
R33 · FY2024 · HL
Reducing the Impact of Rheumatic Heart Disease across the Life Span: The Impact Program$241,595
D43 · FY2024 · TW
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A non-inferiority randomized trial. (GOALIE)$1,913,148
R61 · FY2023 · HL
Reducing the Impact of Rheumatic Heart Disease across the Life Span: The Impact Program$242,449
D43 · FY2023 · TW
Reducing the Impact of Rheumatic Heart Disease across the Life Span: The Impact Program$244,145
D43 · FY2022 · TW